Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sitagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 12/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 1.00 |
| ▸ | ACE | P12821 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | FAP | Q12884 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sitagliptin SCHEMBL31513245 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL29421658 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL174489 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL29365085 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL1289311 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL19520418 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL30885792 | 0.99 | DPP4 (0.98) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL572135 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL1533793 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL18131636 | 0.98 | DPP4 (0.98) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 32260 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636284-B2 | Compositions for use in the prevention and/or treatment of intellectual disability and neurodegenerative diseases in a subject with down syndrome | Universita' Degli Studi Di Roma “La Sapienza” (IT) | 2026-05-26 | — | — | US | claimed |
| WO-2026107262-A1 | PROLONGED, SCAFFOLD-MEDIATED DELIVERY OF ANGIOGENIC COMPOUNDS | EFEMORAL MEDICAL, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026097393-A1 | USE OF ALBIFLORIN FOR PREVENTING AND TREATING DEPRESSION COMORBID WITH METABOLIC SYNDROME AND DEPRESSION COMORBID WITH TYPE II DIABETES | 张作光 | 2026-05-15 | — | — | WO | claimed |
| US-20260124282-A1 | DECORIN FOR ITS USE IN THE TREATMENT OF DIABETES | CENTRE EUROPEEN D'ETUDE DU DIABETE (FR) | 2026-05-07 | — | — | US | claimed |
| EP-4734978-A2 | COMBINATION THERAPIES USING PSILOCYBIN | University of Padova (IT) | 2026-05-06 | — | — | EP | claimed |
| EP-4735023-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | Piton Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-3634453-B1 | PLANT EXTRACTS WITH ANTI-DIABETIC AND OTHER USEFUL ACTIVITIES | HOUSEY PHARMACEUTICAL RES LABORATORIES L L C (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| WO-2006094942-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2006-09-14 | — | — | WO | claimed |
| WO-2006094933-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2006-09-14 | — | — | WO | claimed |
| US-20060160736-A1 | Pharmaceutical compositions and methods for restoring beta-cell mass and function | DIAKINE THERAPEUTICS, INC. (US) | 2006-07-20 | — | — | US | claimed |
| WO-2006074051-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | WO | claimed |
| EP-1667524-A2 | NOVEL CRYSTALLINE FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2006041976-A1 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-04-20 | — | — | WO | claimed |
| WO-2006041797-A2 | ACYCLIC HYDRAZIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-04-20 | — | — | WO | claimed |
| US-20050171112-A1 | Combinations useful for the treatment of neuronal disorders | PROBIODRUG AG | 2005-08-04 | — | — | US | claimed |
| US-20050137142-A1 | Combinations useful for the treatment of neuronal disorders | PROBIODRUG AG | 2005-06-23 | — | — | US | claimed |
| WO-2005030127-A2 | NOVEL CRYSTALLINE FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | claimed |